

1 **Trypanosomal variant surface glycoprotein expression in human**
2 **African trypanosomiasis patients**

3
4 Jaime So^{1**}, Sarah Sudlow^{1**}, Abeer Sayeed¹, Tanner Grudda¹, Stijn Deborggraeve^{2#},
5 Dieudonné Mumba Ngoyi³, Didier Kashiama Desamber⁴, Bill Wickstead⁵, Veerle Lejon⁶,
6 and Monica R. Mugnier^{1*}

7
8
9 ¹Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg
10 School of Public Health, Baltimore, Maryland, United States of America

11
12 ²Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

13
14 ³Department of Parasitology, Institut National de Recherche Biomédicale, Kinshasa,
15 Democratic Republic of the Congo

16
17 ⁴Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine,
18 (PNLTHA), Ministry of Health, Kinshasa, Democratic Republic of the Congo

19
20 ⁵ School of Life Sciences, Queen's Medical Centre, University of Nottingham,
21 Nottingham, NG7 2UH, United Kingdom

22
23 ⁶ UMR-177 Intertryp, Institut de Recherche pour le Développement, Centre de
24 Coopération Internationale en Recherche Agronomique pour le Développement,
25 University of Montpellier, Montpellier, France

26
27
28
29 **These authors contributed equally to the work

30 # Current address: Médecins Sans Frontières - Access Campaign, Geneva, Switzerland

31
32 * Corresponding author

33 E-mail: mmugnie1@jhu.edu (MM)

34

35

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Abstract

Trypanosoma brucei gambiense, an extracellular protozoan parasite, is the primary causative agent of human African Trypanosomiasis. *T. b. gambiense* is endemic to West and Central Africa where it is transmitted by the bite of infected tsetse flies. In the bloodstream of an infected host, the parasite evades antibody recognition by altering the Variant Surface Glycoprotein (VSG) that forms a dense coat on its cell surface through a process known as antigenic variation. Each VSG has a variable N-terminal domain that is exposed to the host and a less variable C-terminal domain that is at least partially hidden from host antibodies. Our lab developed VSG-seq, a targeted RNA-seq method, to study VSG expression in *T. brucei*. Studies using VSG-seq to characterize antigenic variation in a mouse model have revealed marked diversity in VSG expression within parasite populations, but this finding has not yet been validated in a natural human infection. Here, we used VSG-seq to analyze VSGs expressed in the blood of twelve patients infected with *T. b. gambiense*. The number of VSGs identified per patient ranged from one to fourteen and, notably, two VSGs were shared by more than one patient. Analysis of expressed VSG N-terminal domain types revealed that 82% of expressed VSGs encoded a type B N-terminus, a bias not seen in datasets from other *T. brucei* subspecies. C-terminal types in *T. b. gambiense* infection were also restricted. These results demonstrate a bias either in the underlying VSG repertoire of *T. b. gambiense* or in the selection of VSGs from the repertoire during infection. This work demonstrates the feasibility of using VSG-seq to study antigenic variation in human infections and highlights the importance of understanding VSG repertoires in the field.

62 **Author Summary**

63

64 Human African Trypanosomiasis is a neglected tropical disease largely caused by the
65 extracellular parasite known as *Trypanosoma brucei gambiense*. To avoid elimination
66 by the host, these parasites repeatedly replace their dense surface coat of Variant
67 Surface Glycoprotein (VSG). Despite the important role of VSGs in prolonging infection,
68 VSG expression during natural human infections is poorly understood. A better
69 understanding of natural VSG expression dynamics can clarify the mechanisms which
70 *T. brucei* uses to alter its VSG coat and improve how trypanosomiasis is diagnosed in
71 humans. We analyzed the expressed VSGs detected in the blood of patients with
72 trypanosomiasis. Our findings indicate that a diverse range of VSGs are expressed in
73 both natural and experimental infections.

74

75 Introduction

76
77 Human African Trypanosomiasis (HAT) is caused by the protozoan parasite
78 *Trypanosoma brucei*. *T. brucei* and its vector, the tsetse fly, are endemic to sub-
79 Saharan Africa [1]. There are two human-infective *T. brucei* subspecies: *T. b.*
80 *gambiense* which causes chronic infection in West and Central Africa (~98% of cases)
81 and *T. b. rhodesiense* which causes acute infection in East and Southern Africa (~2% of
82 cases) [2,3]. In humans, infections progress from an early stage that is generally
83 marked by a fever and body aches to a late stage that begins once the parasite crosses
84 the blood-brain barrier and is accompanied by the development of severe neurological
85 symptoms [4]. HAT is considered fatal without timely diagnosis and treatment. While
86 around 50 million people are at risk of infection [5], the number of annual human
87 infections has declined significantly in recent years, with only 864 cases reported in
88 2019 [6]. The World Health Organization is working towards zero human transmissions
89 of HAT caused by *T. b. gambiense* (gHAT) by 2030 [7]. Current public health initiatives
90 to control the disease depend on case detection and treatment, complemented with
91 vector control.

92
93 Prospects for developing a vaccine are severely confounded by the ability of African
94 trypanosomes to alter their surface antigens [8]. As *T. brucei* persists extracellularly in
95 the blood, lymph, and tissue fluids of the host, it is constantly exposed to host
96 antibodies[9–12]. To evade immune recognition, the parasite periodically changes its
97 dense Variant Surface Glycoprotein (VSG) coat. This process, referred to as antigenic
98 variation, relies on a vast collection of thousands of VSG-encoding genes[13–16]. *T.*
99 *brucei* also continually expands the number of usable antigens by constructing mosaic
100 VSGs—the result of one or more recombination events between individual VSG genes
101 [17,18]

102
103 The VSG contains two domains: a variable N-terminal domain of ~350-400 amino acids
104 and a less variable C-terminal domain of ~40-80 amino acids, characterized by one or
105 two conserved groups of four disulfide-bonded cysteines [13,19]. On the surface of
106 trypanosomes, the VSG N-terminal domain is readily exposed to the host, while the C-
107 terminal domain is proximal to the plasma membrane and largely hidden from host
108 antibodies [20–22]. The N-terminal domain has been classified into two types, A and B,
109 each of which is classified into subtypes (A1-3 and B1-2). The C-terminal domain has
110 been classified into six types (1-6) [13,19]. These classifications are based on protein
111 sequence patterns anchored by the conservation of cysteine residues. The biological
112 implications of these VSG domain types have not been investigated.

113
114 Little is known about how the large genomic repertoire of VSGs is used in natural
115 infections; the number and diversity of VSGs expressed by wild parasite populations
116 remains unknown. One VSG in particular, LiTat 1.3, has been identified as an antigen
117 against which a large percentage of gHAT patients have antibodies [23]. As a result,
118 LiTat 1.3 is the main target antigen in the primary serological screening tool used for
119 gHAT, a test known as the card agglutination test for trypanosomiasis (CATT/*T. b.*
120 *gambiense*)[24]. Despite the widespread use of the CATT to screen for gHAT there are

121 shortcomings: not only can the CATT provide false negatives, but there are also *T. b.*
122 *gambiense* strains that lack the LiTat 1.3 gene entirely [25,26]. More recently developed
123 rapid diagnostic tests use a combination of native LiTat1.3 and another VSG, LiTat1.5
124 [27,28], or a combination of a VSG with the invariant surface glycoprotein ISG 65 [29].
125 Currently there is no serological test for diagnosis of infection with *T. b. rhodesiense*.
126

127 Given the role of VSGs during infection and their importance in gHAT screening tests, a
128 better understanding of VSG expression dynamics could inform the development of
129 improved screening tests while providing insight into the molecular mechanisms of
130 antigenic variation. We developed VSG-seq, a targeted RNA-sequencing method that
131 identifies the VSGs expressed in any population of *T. brucei* and measures the
132 prevalence of each VSG in the population [30]. In a proof-of-principle study, we used
133 VSG-seq to gain insight into the number and diversity of VSGs expressed during
134 experimental mouse infections [30]. This study revealed significant VSG diversity within
135 parasite populations, yet found many of the same VSGs were expressed in different
136 infections, supporting previous reports of a “semi-predictable” order to VSG switching
137 [17,31,32]. Recently, similar high-throughput sequencing methods have been used to
138 characterize antigenic variation in experimental infections of natural hosts for two
139 related African trypanosome species, *T. vivax* and *T. congolense* [33–35], suggesting
140 that the mechanism for antigen production in some animal parasites is different from the
141 *T. brucei* model.
142

143 Whether or not findings from experimental studies of antigenic variation translate to
144 natural *T. brucei* infections is currently unknown. To our knowledge, only one study has
145 investigated VSG expression in wild *T. brucei* isolates [36]. For technical reasons, this
146 study relied on RNA isolated from parasites that were passaged through small animals
147 after collection from the natural host. As VSG expression may change during passage,
148 the data obtained from these samples is somewhat difficult to interpret. To gain a better
149 understanding of the characteristics of antigenic variation in natural *T. brucei* infections,
150 we sought to analyze VSG expression in *T. brucei* field isolates from which RNA was
151 directly extracted.
152

153 In this study, we used VSG-seq to determine the number and diversity of VSGs
154 expressed by *T. b. gambiense* in the blood of twelve patients with a *T. b. gambiense*
155 infection. To complement these data, we also analyzed published datasets from both
156 experimental mouse infections and *T. b. rhodesiense* patients. Our analysis revealed
157 that there is diverse expression of VSGs in natural *T. brucei* infections, and *T. b.*
158 *gambiense* infections show distinct biases in VSG expression that may be unique to this
159 subspecies.

160 **Methods**

161

162 **Ethics statement**

163 The blood specimens from *T.b. gambiense* infected patients were collected within the
164 projects “Longitudinal follow-up of CATT seropositive, trypanosome negative individuals
165 (SeroSui) and “An integrated approach for identification of genetic determinants for sus-
166 ceptibility for trypanosomiasis (TrypanoGEN) [37]. In France, the SeroSui study received
167 approval from the “Comité Consultatif de Déontologie et d’Ethique” (CCDE) of the French
168 National Institute for Sustainable Development Research (IRD, May 2013 session), and
169 in Belgium from the Institutional Review Board of the Institute of Tropical Medicine (refer-
170 ence 886/13) and from the Ethics Committee of the University of Antwerp
171 (B300201318039). In DR Congo, the projects SeroSui and TrypanoGEN were approved
172 by the Ministry of Health through the Ngaliema Clinic of Kinshasa (references 422/2013
173 and 424/2013). Participants gave their written informed consent to participate in the pro-
174 jects. For minors, additional written consent was obtained from their legal representative.

175

176

177 **Patient Enrollment and Origin Map**

178 Patients originated from the Democratic Republic (DR) of the Congo and were identified
179 in the second half of 2013, either during passive screening at the center for HAT
180 diagnosis and treatment of the hospital of Masi Manimba, or during active screening by
181 the mobile team of the national sleeping sickness control program (PNLTHA) in Masi
182 Manimba and Mosango health zones (Kwilu province, DR Congo). Individuals were
183 screened for the presence of specific antibodies in whole blood with the CATT test. For
184 those reacting blood positive in CATT, twofold serial plasma dilutions of 1/2-1/32 were
185 also tested and the CATT end titer was determined. CATT positives underwent
186 parasitological confirmation by direct microscopic examination of lymph (if enlarged
187 lymph nodes were present), and examination of blood by the mini-anion exchange
188 centrifugation technique on buffy coat [38]. Individuals in whom trypanosomes were
189 observed underwent lumbar puncture. The cerebrospinal fluid was examined for white
190 blood cell count and presence of trypanosomes to determine the disease stage and
191 select the appropriate treatment. The patients were questioned about their place of
192 residence, the geographic coordinates of the corresponding villages were obtained from
193 the atlas of HAT [39] and plotted on a map of the DR Congo using ArcGIS® software by
194 Esri. Distances were determined and a distance matrix generated (see Supplemental
195 Table 2).

196

197

198 **Patient Blood Sample Collection and Total RNA Isolation**

199 A 2.5 mL volume of blood was collected from each patient in a PAXgene Blood RNA
200 Tube. The blood was mixed with the buffer in the tube, aliquoted in 2 mL volumes and
201 frozen in liquid nitrogen for a maximum of two weeks. After arrival in Kinshasha, tubes
202 were stored at -70°C. Total RNA was extracted and isolated from each blood sample as
203 previously described [40].

204

205

206 **Estimation of Parasitemia**

207 Two approaches were used to estimate parasitemia. First, a 9 mL volume of blood on
208 heparin was centrifuged, 500 microliters of the buffy coat were taken up and
209 trypanosomes were isolated using the mini-anion exchange centrifugation technique.
210 After centrifugation of the column eluate, the number of parasites visible in the tip of the
211 collection tube were estimated. Second, Spliced Leader (SL) RNA expression levels
212 were measured by real-time PCR as previously described [40]. A Ct value was
213 determined for each patient blood sample. Real-time PCR was performed on RNA
214 samples before reverse transcription to verify the absence of DNA contamination.

215

216

217 **RNA-sequencing**

218 DNase I-treated RNA samples were cleaned up with 1.8x Mag-Bind TotalPure NGS
219 Beads (Omega Bio-Tek, # M1378-01). cDNA was generated using the SuperScript III
220 First-strand synthesis system (Invitrogen, 18080051) according to manufacturer's
221 instructions. Eight microliters of each sample (between 36 and 944 ng) were used for
222 cDNA synthesis, which was performed using the oligo-dT primer provided with the kit.
223 This material was cleaned up with 1.8x Mag-Bind beads and used to generate three
224 replicate library preparations for each sample. These technical replicates were
225 generated to ensure that any VSGs detected were not the result of PCR artifacts[41,42].
226 Because the number of parasites in each sample was expected to be low, we used a
227 nested PCR approach for preparing these VSG-seq libraries. First, we amplified *T.*
228 *brucei* cDNA from the parasite/host cDNA pool by PCR using a spliced leader primer
229 paired with an anchored oligo-dT primer (SL-1-nested and anchored oligo-dT;
230 Supplemental Table 1). 20 cycles of PCR were completed (55°C annealing, 45s
231 extension) using Phusion polymerase (Thermo Scientific, #F530L). PCR reactions were
232 cleaned up with 1.8x Mag-Bind beads. After amplifying *T. brucei* cDNA, a VSG-specific
233 PCR reaction was carried out using M13RSL and 14-mer-SP6 primers (see primers;
234 Supplemental Table 1). 30 cycles of PCR (42°C annealing, 45s extension) were
235 performed using Phusion polymerase. Amplified VSG cDNA was then cleaned up with
236 1X Mag-Bind beads and quantified using a Qubit dsDNA HS Assay (Invitrogen
237 Q32854). Sequencing libraries were prepared from 1 ng of each VSG PCR product
238 using the Nextera XT DNA Library Preparation Kit (Illumina, FC-131-1096); this was
239 done according to the manufacturer's protocol with the exception of the final cleanup
240 step which was performed using 1X Mag-Bind beads. Single-end 100bp sequencing
241 was performed on an Illumina HiSeq 2500. Raw data are available in the NCBI
242 Sequence Read Archive under accession number PRJNA751607.

243

244

245 **VSG-seq analysis of *T. b. gambiense* and *T. b. rhodesiense* sequencing libraries**

246 For the analysis of both *T. b. gambiense* (VSG-seq preparations) and *T. b. rhodesiense*
247 (traditional mRNA sequencing library preparations; sequences were obtained from ENA,
248 accession numbers PRJEB27207 and PRJEB18523) raw reads were processed using
249 the VSG-seq pipeline available at <https://github.com/mugnierlab/VSGSeqPipeline>.
250 Briefly, VSG transcripts were assembled *de novo* from quality- and adapter-trimmed
251 reads for each sample (patient or patient replicate) from raw reads using Trinity (version

252 5.26.2) [43]. Contigs containing open reading frames (ORFs) were identified as previ-
253 ously described [30]. ORF-containing contigs were compared to Lister427 and
254 EATRO1125 VSGs as well as a collection of known contaminating non-VSG se-
255 quences. Alignments to VSGs with an E-value below 1×10^{-10} that did not match any
256 known non-VSG contaminants were identified as VSG transcripts. For *T. b. gambiense*
257 replicate libraries, VSG ORFs identified in any patient replicate were consolidated into a
258 sole reference genome for each patient using CD-HIT (version 4.8.1)[44] with the follow-
259 ing arguments: -d 0 -c 0.98 -n 8 -G 1 -g 1 -s 0.0 -aL 0.0. Final VSG ORF files were man-
260 ually inspected. Two *T. b. gambiense* patient VSGs (Patients 11 and 13) showed likely
261 assembly errors. In one case a VSG was duplicated and concatenated, and in another
262 two VSGs were concatenated. These reference files were manually corrected (removing
263 the duplicate or editing annotation to reflect two VSGs in the concatenated ORF) so that
264 each VSG could be properly quantified. VSG reference databases for each patient are
265 available at <https://github.com/mugnierlab/Tbgambiense2021/>. For *T. b. gambiense*,
266 reads from each patient replicate were then aligned to that patient's consolidated refer-
267 ence genome using Bowtie with the parameters -v 2 -m 1 -S (version 1.2.3)[45]. For *T.*
268 *b. rhodesiense*, each patient's data was aligned to its own VSG ORF assembly. RPKM
269 values for VSG expression in each sample were generated using MULTo (version 1.0)
270 [46], and the percentage of parasites in each population expressing a VSG was calcu-
271 lated as described previously [30]. For *T. b. gambiense* samples, we included only
272 VSGs with an expression measurement above 1% in two or more patient replicates in
273 our analysis. For *T. b. rhodesiense* samples, we included only VSGs with expression
274 >0.01%. To compare VSG expression between patients, despite the different reference
275 genomes used for each patient, CD-HIT was used to cluster VSG sequences with
276 greater than 98% similarity among patients, using the same parameters as were used
277 for consolidation of reference VSG databases before alignment. Each unique VSG clus-
278 ter was given a numerical ID (e.g. Gambiense #) and the longest sequence within each
279 group was chosen to represent the cluster. Clusters representing TgSGP and SRA were
280 manually removed from the expressed VSG sets before analysis. R code used for anal-
281 ysis of resulting data and the generation of figures is available at
282 <https://github.com/mugnierlab/Tbgambiense2021/>.

283
284

285 **Analysis of VSG N-terminal Domains**

286
287

287 Genomic VSG sequences

288

289 The VSG repertoires of *T. b. brucei* Lister427 ("Lister427_2018" assembly), *T. b. brucei*
290 TREU927/4 and *T. b. gambiense* DAL972 were taken from TriTrypDB (v50). The *T. b.*
291 *brucei* EATRO 1125 VSGnome was used for analysis of the EATRO1125 VSG
292 repertoire (vsgs_tb1125_nodups_atleast250aas_pro.txt, available at
293 <https://tryps.rockefeller.edu/Sequences.html> or GenBank accession KX698609.1 -
294 KX701858.1). Likely VSG N-termini were identified as predicted proteins with significant
295 similarity (e-value $\leq 10^{-5}$) to hidden Markov models (HMMs) of aligned type A and B
296 VSG N-termini taken from [15]. VSG sequences from other strains (except those
297 generated by VSG-seq) were taken from the analysis in Cross, et al. [15].

298

299 N-terminal domain phylogenies

300 Phylogenies of VSG N-termini based on unaligned sequence similarities were
301 constructed using the method described in [47] and used previously to classify VSG
302 sequence [15]. N-termini were extracted as all predicted protein sequence up to the C-
303 terminal end of the bounding envelope of the match to either type-A or type-B HMM
304 (whichever was longer). A matrix of similarities between all sequences was constructed
305 from normalized transformed BLASTp scores as in Wickstead, et al. [47] and used to
306 infer a neighbor-joining tree using QuickTree v1.1 [48]. Trees were annotated and
307 visualized in R with the package APE v5.2 [49].

308

309 HMM

310 For N-terminal typing by HMM, we used a python analysis pipeline available at
311 (https://github.com/mugnierlab/find_VSG_Ndomains). The pipeline first identifies the
312 boundaries of the VSG N-terminal domain using the type A and type B HMM profiles
313 generated by Cross *et al.* which includes 735 previously-typed VSG N-terminal domain
314 sequences [15]. N-terminal domains are defined by the largest envelope domain
315 coordinate that meets e-value threshold (1×10^{-5} , --domE 0.00001). In cases where no
316 N-terminal domain is identified using these profiles, the pipeline executes a “rescue”
317 domain search in which the VSG is searched against a ‘pan-VSG’ N-terminus profile we
318 generated using 763 previously-typed VSG N-terminal domain sequences. This set of
319 VSGs includes several *T. brucei* strains and/or subspecies: Tb427 (559), TREU927
320 (138), *T. b. gambiense* DAL972 (28), EATRO795 (8), EATRO110 (5), *T. equiperdum*
321 (4), and *T. evansi* (21). The N-terminal domain type of these VSGs were previously
322 determined by Cross et. al (2014) by building neighbor-joining trees using local
323 alignment scores from all-versus-all BLASTp similarity searches [15]. Domain
324 boundaries are called using the same parameters as with the type A and B profiles.

325

326 After identifying boundaries, the pipeline extracts the sequence of the N-terminal
327 domain, and this is searched against five subtype HMM profiles. To generate N-terminal
328 domain subtype HMM profiles, five multiple sequence alignments were performed using
329 Clustal Omega [50] with the 763 previously-typed VSG N-terminal domain sequences
330 described above; each alignment included the VSG N-terminal domains of the same
331 subtype (A1, A2, A3, B1, and B2). Alignment output files in STOCKHOLM format were
332 used to generate distinct HMM profiles for type A1, A2, A3, B1, and B2 VSGs using the
333 pre-determined subtype classifications of the 763 VSGs using HMMer version 3.1b2
334 [51]. The number of sequences used to create each subtype profile ranged from 75 to
335 211. The most probable subtype is determined by the pipeline based on the highest
336 scoring sequence alignment against the subtype HMM profile database when HMMscan
337 is run under default alignment parameters. The pipeline generates a FASTA file
338 containing the amino acid sequence of each VSG N-terminus and a CSV with
339 descriptions of the N-terminal domain including its type and subtype.

340

341 Network graph

342 N-terminal network graphs were made using VSG N-terminal domains from TriTrypDB
343 Lister427_2018 and *T. b. gambiense* DAL972 (v50) VSG sets described above, and the

344 *T. b. gambiense* and *T. b. rhodesiense* VSG N-termini which met our expression
345 thresholds. Identified N-terminal domains were then subjected to an all-versus-all
346 BLASTp. A pairwise table was created that includes each query-subject pair, the
347 corresponding alignment E-value, and N-terminal domain type of the query sequence if
348 previously typed in Cross, et al. [15]. Pseudogenes and fragments were excluded from
349 the Lister427_2018 reference prior to plotting by filtering for VSG genes annotated as
350 pseudogenes and any less than 400 amino acids in length, as the remaining sequences
351 are most likely to be full length VSG. Network graphs were generated with the igraph R
352 package[52] using undirected and unweighted clustering of nodes after applying link
353 cutoffs based on E-value $< 10^{-2}$. The leading eigenvector clustering method [53] was
354 used to detect and assign nodes to communities based on clustering
355 (cluster_leading_eigen() method in igraph).

356
357
358

359 **Analysis of VSG C-terminal Domain Types**

360
361 VSG C-termini were extracted from expressed *T. b. gambiense* VSGs, *T.b. gambiense*
362 DAL972 (v50), and 545 previously-typed VSG C-termini from the Lister 427 strain using
363 the C-terminal HMM profile generated by Cross et al.[15], and the same HMMscan
364 parameters as for N-termini (E-value $< 1 \times 10^{-5}$; largest domain based on envelope
365 coordinates). An all-vs-all BLASTp was performed on these sequences, and network
366 graphs were generated in the same manner as the N-terminal network graphs. Links
367 were drawn between C-termini with a BLASTp E-value $\leq 1 \times 10^{-3}$. The leading
368 eigenvector method for clustering [53] was used to detect and assign nodes to
369 communities based on clustering (cluster_leading_eigen() method in igraph).
370

371

372 Results

373

374 Parasites in gHAT patients express diverse sets of VSGs

375

376 To investigate VSG expression in natural human infections, we performed VSG-seq on
377 RNA extracted from whole blood collected from twelve human African trypanosomiasis
378 patients from five locations in the Kwilu province of the Democratic Republic of Congo
379 (Fig 1A). The relative parasitemia of each patient was estimated by SL-QPCR [54], and
380 the number of parasites after mAECT on buffy coat was estimated for all patients except
381 patient 29 (Table 1). RNA extracted from 2.5 mL of whole blood from each patient was
382 used to prepare libraries for VSG-seq. *T. brucei* RNA was amplified from host/parasite
383 total RNA using a primer against the *T. brucei* spliced leader sequence and an
384 anchored oligo-dT primer. The resulting trypanosome-enriched cDNA was then used as
385 a template to amplify VSG cDNA. VSG amplicons were then submitted to VSG-seq
386 sequencing and analysis. To determine whether a VSG was expressed within a patient,
387 we applied the following stringent cutoffs:

388

- 389 1) We conservatively estimated that each 2.5 mL patient blood sample
390 contained a minimum of 100 parasites. At this minimum parasitemia, a single
391 parasite would represent 1% of the population (and consequently ~1% of the
392 parasite RNA in a sample). As a result, we excluded all VSGs expressed by
393 <1% of the population as estimated by VSG-seq.
- 394 2) We classified VSGs as expressed if they met the expression cutoff in at least
395 two of three technical library replicates.

396

397 1112 unique VSG open reading frames were assembled *de novo* in the patient set and
398 44 met our expression criteria. Only these 44 VSGs, which we will refer to as
399 “expressed VSGs” in these patient samples, were considered in downstream analysis,
400 except when otherwise noted. TgsGP, the VSG-like protein which partially enables
401 resistance to human serum in *T. b. gambiense* [55], was assembled in samples from
402 patients 2, 11, 13, and 17, and met expression threshold in patients 2, 11, and 17. The
403 absence of this transcript in most samples is likely a result of the low amount of input
404 material used to prepare samples. Notably, none of the expressed VSGs shared
405 similarity with any VSGs in the *T. b. gambiense* DAL972 genome or the diagnostic
406 VSGs LiTat 1.3, LiTat 1.5 and LiTat 1.6.

407



408 At least one VSG met our expression criteria in each patient, and in most cases multiple
409 VSGs were detected. The highest diversity was observed in patient 2, with 14 VSGs
410 expressed (Fig 1B, Supplemental Figure 1). We observed a correlation between
411 parasitemia as estimated by QPCR and number of VSGs (Supplemental Figure 2),
412 suggesting that these samples do not reflect the full diversity of each population.
413 Nevertheless, two VSG were shared between patients: VSG ‘Gambiense 195’ was
414 expressed in both patient 12 and patient 17 from Village C, and VSG ‘Gambiense 38’
415 was expressed in patient 12 from Village C and patient 23 from Village D which are 40
416 kilometers apart (Fig 1C).

Patient	Location	Est. parasites in 500 μ L buffy coat	mean SL-RNA Ct	Plasma CATT end dilution	WBC	Parasites in CSF	Stage
1	Village A	>50	22.155	≥ 32	1	-	First
2	Village A	>50	19.020	≥ 32	6	-	Early 2nd
3	Village A	2-5	28.780	≥ 32	6	-	Early 2nd
11	Village C	>50	22.030	4	9	-	Early 2nd
12	Village C	6-20	25.430	≥ 32	6	-	Early 2nd
13	Village C	6-20	26.635	16	12	-	Early 2nd
17	Village C	21-50	24.495	≥ 32	13	-	Early 2nd
19	Village C	1	28.245	8	7	-	Early 2nd
23	Village D	6-20	27.085	≥ 32	2	-	First
29	Village B	-	28.320	≥ 32	3	-	First
30	Village B	>50	22.960	≥ 32	694	+	Severe 2nd
33	Village E	1	32.385	≥ 32	2	-	First


417
418

419 **Table 1. Patient stage and parasitemia data.** For staging, the following definitions were used:
420 First: 0-5 WBC/ μ L, no trypanosomes in CSF. Second: >5 WBC/ μ L or trypanosomes in CSF. (with
421 early 2nd 6-20 WBC/ μ L and no trypanosomes in CSF; severe 2nd: >100 WBC/ μ L). WBC: white
422 blood cells.


A



B



C



423

424 **Figure 1. Parasites isolated from gHAT patients express multiple VSGs.** (A) Map showing
425 the location of each patient's home village. Maps were generated with ArcGIS® software by
426 Esri, using world imagery and National Geographic style basemaps. (B) Graph depicting the

427 total number of VSGs expressed in each patient. (C) The intersection of expressed VSG sets in
428 each patient. Color indicates patient origin.

429

430 **Natural *T. b. gambiense* infections show a strong bias towards expression of type**
431 **B VSG**


432

433 To further characterize the set of expressed VSGs in these samples, we sought a fast
434 and unbiased method for determining the type and subtype of each VSG's N-terminal
435 domain. We evaluated two approaches. The first approach was to create a bioinformatic
436 pipeline to determine each N-terminal domain subtype, using HMM profiles we created
437 for each subtype using sets of N-terminal domains previously typed by Cross *et al.* [15].
438 The second approach was to create a BLASTp network graph based on a previously
439 published method [56] where the N-terminal subtype of a VSG is determined by the set
440 of VSGs it clusters with, and clusters are identified using the leading eigenvector
441 method [53]. We used each approach to determine the N-terminal subtype of each
442 expressed VSG in our patient sample dataset along with 863 VSG N-termini from the
443 Lister 427 genome. We compared these results to either existing N-terminal
444 classification (for Lister 427 VSGs) or classification based on position in a newly-
445 generated BLASTp-tree[15] (for *T. b. gambiense* VSGs; Figure 2A). Both the new HMM
446 profile and BLASTp network graph approaches generally recapitulated previous VSG
447 classification based on BLASTp-tree, with all three methods agreeing 93.7% of the time
448 (Figure 2B). The HMM pipeline method agreed with BLASTp-tree typing for all patient
449 VSGs, while the network graph approach agreed for 43/44 VSGs (Figure 2B,
450 Supplemental Fig 3, Supplemental Table 1) [15]. It is not surprising that the HMM
451 pipeline would better reflect the results of the BLASTp-tree method, as the N-terminal
452 subtype HMM profiles were generated using VSGs classified by this method. Based on
453 these data, we determined the HMM method is a fast and accurate method for
454 determining the N-terminal domain types of unknown VSGs.

455

456 Our N-terminal domain typing pipeline identified the domain sequence and type for all
457 44 patient VSGs (Fig 2C). 82% of the expressed *T. b. gambiense* VSGs had type B N-
458 terminal domains, and within each patient 50% or more of expressed VSG were type B.
459 This bias was not restricted to highly expressed VSGs, as 74.5% of all assembled VSG
460 (813 of 1091 classifiable to an N-terminal subtype) were also type B. This observation
461 motivated further investigation into the expressed N-terminal domains in infections by
462 other *T. brucei* subspecies.

463



464
465
466
467
468
469
470
471
472
473
474
475

Figure 2. *T. b. gambiense* samples show a bias towards expression of type B VSG. (A) Visualization of relatedness between N-terminal domain peptide sequences inferred by Neighbor-Joining based on normalized BLASTp scores. Legend indicates classification by HMM pipeline (for Lister 427 VSGs, to highlight agreement between the two methods), or by subspecies for VSGs expressed in patients. (B) Agreement between three VSG typing methods for Lister 427 VSG set and the expressed *T. b. gambiense* patient VSG set. (C) N-terminal domain subtype composition of expressed *T. b. gambiense* VSGs as determined by HMM analysis pipeline.

476 **Type B VSG bias is not observed in natural *T. b. rhodesiense* infection.**


477

478 To determine whether the bias towards type B VSGs was unique to *T. b. gambiense*
479 infections, we analyzed RNA-seq data from a published study measuring gene
480 expression in the blood and cerebrospinal fluid (CSF) of *T.b. rhodesiense* patients in
481 Northern Uganda [57]. These libraries were prepared conventionally after either rRNA-
482 depletion for blood or poly-A selection for CSF samples. We analyzed only those
483 samples for which at least 10% of reads mapped to the *T. brucei* genome. Raw reads
484 from these samples were subjected to the VSG-seq analysis pipeline, and because the
485 estimated parasitemia of these patients was much higher than our *T.b. gambiense*
486 study, we adjusted our expression criteria accordingly to 0.01%, the published limit of
487 detection of VSG-seq [30]. Using this approach, we identified 77 unique VSG
488 sequences across all blood and CSF samples (Fig 3A, Supplemental Figure 4). SRA,
489 the VSG-like protein that confers human serum resistance in *T. b. rhodesiense* [58],
490 was expressed in all patient samples.

491

492 The HMM pipeline was able to determine types for 74 of these VSG sequences; the
493 remaining appeared to be incompletely assembled, presumably due to insufficient read
494 depth from their low level of expression. In each patient, multiple VSGs assembled and
495 a large proportion were expressed in multiple patients (Fig 3B), in line with our
496 observations in experimental mouse infections. Although the majority of VSGs detected
497 in these patients were type B (57%), this VSG type was much less predominant than in
498 *T. b. gambiense* infection (Fig 3C). Interestingly, there was no overlap in expressed
499 VSGs in the blood and CSF of patient 71, the only patient for which both blood and CSF
500 data were available for analysis, potentially indicating that different organs or body
501 compartments harbor different sets of VSGs.

502



503

504 **Figure 3. *T. b. rhodesiense* samples reveal diverse VSG expression, but little N-terminal**
 505 **type bias.** (A) The total number of expressed *T. b. rhodesiense* VSG in each patient and
 506 sample type. Bar color represents sample type from which RNA was extracted. (B) N-terminal
 507 domain subtype composition of all expressed VSGs. (C) Intersections of VSGs expressed in
 508 multiple infections. Color represents the sample type.

509


510

511 **The predominant VSG N-terminal type fluctuates over time during experimental *T.***
 512 ***b. brucei* infection**

513

514 One explanation for the bias towards type B VSG in *T. b. gambiense* could be that VSG
 515 type fluctuates over time. This is plausible because patient samples only represent a
 516 single moment during infection, and *T. b. gambiense* samples are more likely to be
 517 obtained at a later stage of infection than *T. b. rhodesiense*. To investigate whether a

518 predominance of type B VSGs could be a feature of the chronic nature of *T. brucei*
519 *gambiense* infection, we took advantage of our published VSG-seq analysis of parasites
520 isolated from mice infected with the *T.b. brucei* EATRO1125 strain. Blood was collected
521 over time during this study, providing data from days 6/7, 12, 14, 21, 24, 26, and 30 post
522 infection in all four mice, and from days 96, 99, 102, and 105 in one of the four mice
523 (Mouse 3). Of 192 unique VSGs identified between days 0-30 and 97 VSGs identified
524 between days 96-105, 190 and 93 VSGs were typed by the python HMM pipeline,
525 respectively. The remaining VSGs were incompletely assembled by Trinity. Our analysis
526 of VSG types over time revealed that the predominantly expressed N-terminal domain
527 type fluctuates between type A and type B throughout the early stages of infection as
528 well as in extended chronic infections (Fig 4). Parasitemia did not correlate with either
529 the diversity of VSG expression or N-terminal domain type predominance
530 (Supplemental Fig 3). Because all patient samples were collected from a single
531 timepoint, it remains unclear whether the predominant N-terminal type fluctuates in
532 human infections over time as it does in mice.
533



534


535 **Figure 4. VSG N-terminal type composition fluctuates over the course of infection**
536 **in mice.** Proportions of N-terminal domain types expressed in *T. b. brucei* infected mice over
537 time. Total number of identified VSGs is represented by the black dotted line. A) N-terminal type
538 composition days 0-30. B) Type composition days 96-105.

539

540 **The composition of the genomic VSG repertoire is reflected in expressed VSG N-**
541 **terminal domain types**

542
543 Another source for bias in expressed VSG type is the composition of the genomic VSG
544 repertoire. We were only able to make a direct comparison between the genomic and
545 expressed VSG repertoire for EATRO1125 mouse infections, as the 'VSGnome' for this
546 strain has been sequenced. This analysis revealed that, although the predominant N-
547 terminal VSG type fluctuates during infection, the expressed VSG repertoire generally
548 reflects the composition of the genomic repertoire (chi-squared $p = 0.0515$, Figure 5A).

549
550 Unfortunately, the full repertoire of VSGs encoded by most trypanosome strains is
551 unknown, so such a direct comparison is impossible for *T. b. gambiense* and *T. b.*
552 *rhodesiense* patient samples. The *T. b. gambiense* DAL972 reference genome lacks
553 most of the genomic regions containing the majority of VSGs (haploid arrays,
554 expression sites, and minichromosomes), and there is no publicly available *T. b.*
555 *rhodesiense* reference assembly. However, there is no significant difference in VSG
556 type frequency comparing the expressed *T. b. rhodesiense* set to the closely related
557 and near-complete *T. b. brucei* Lister 427 repertoire [59] (chi-squared p -value = 0.2422)
558 (Fig 5B). Similarly, the proportion of N-terminal domains identified in the *T. b.*
559 *gambiense* patient samples is not statistically different from the incomplete *T. b.*
560 *gambiense* DAL972 genomic repertoire (chi-squared p -value = 0.0575) (Fig 5B). Both *T.*
561 *b. gambiense* patient VSG (chi-squared p -value = $2.413e-4$) and the 54 VSGs identified
562 in *T. b. gambiense* DAL972 (chi-square p -value = 0.0301) have A and B type
563 frequencies that differ significantly from Lister427. Though these results should be
564 interpreted with caution given the limitations of the reference genomes being used, they
565 generally suggest that the underlying genomic VSG repertoire of *T. b. gambiense* differs
566 from other subspecies in its N-terminal type composition.
567



568

569 **Figure 5. VSG expression reflects the genomic VSG repertoire of the infecting parasites.**

570 (A) Columns show the proportion of VSG types identified in each mouse infection over all time
 571 points. Total number of unique VSG sequences displayed above column. Mouse infections were
 572 initiated with *T.b. brucei* strain EATRO 1125. (B) A comparison of the frequencies of type A and
 573 B VSGs expressed in patients and those present in Lister 427 and DAL972 reference genomes.

574


575 ***T.b. gambiense* expressed VSG C-terminal domains show a bias for type 2**
576 **domains**

577

578 In addition to examining N-terminal types in our *T. b. gambiense* dataset, we also
579 examined expressed VSG C-termini. Previous studies defined six C-terminal types,
580 although resolution of these types in larger VSG sets has been difficult due to the high
581 level of similarity among VSG C-termini [15,56]. In line with previous observations, a
582 BLASTp-tree analysis of assembled *T.b. gambiense* C-terminal domains revealed
583 frequent sequence similarity between expressed C-terminal types but did not provide
584 sufficient resolution to confidently assign types (Fig 6A).

585

586 To supplement this analysis, we also performed a network graph analysis. Although this
587 method had previously performed poorly in resolving VSG C-termini [56], using the
588 leading eigenvector clustering method [53] to define community membership within the
589 graph allowed a faithful reconstitution of the C-terminal types previously determined by
590 BLASTp tree analysis. Using this approach, we were able to tentatively assign C-termini
591 domain types to the *T. b. gambiense* VSGs (Fig 6B). Most patient C-terminal domain
592 types were type 2, while the remaining largely fell into the type 1 category. Only one
593 type 3 C-terminus was identified in the patient set. Although there are very few VSG C-
594 termini available in the *T. b. gambiense* DAL972 genome, these sequences show a pre-
595 dominance of types 3 and 5, while the genomic repertoire of C-termini in Lister427
596 shows roughly equivalent representation of types 1, 2, and 3. Unlike *T. b. gambiense* N-
597 termini, the expressed C-termini were more restricted than the sets of C-termini appar-
598 ently available in the *T. b. gambiense* DAL972 or *T. b. brucei* Lister427 genomes
599 (Fisher's exact test, p-value < 1×10^{-5}). In line with previous observations, we saw no evi-
600 dence of domain exclusion: a C-terminal domain of one type could be paired with any
601 type of N-terminal domain (Fig 6E)[20]. As observed in our analysis of expressed N-ter-
602 mini, C-terminal domain types were not correlated to geographical origin (Fig 6F). Over-
603 all, these data suggest that, like N-termini, expressed VSG C-termini are also biased to-
604 wards certain C-terminal types. Unlike N-termini, however, C-terminal types expressed
605 in *T. b. gambiense* infection may not reflect the composition of the parasite's genomic
606 repertoire.



608 **Figure 6. Expressed VSG C-termini are primarily type 1 and type 2.** A) BLASTp tree of C-
609 terminal domains. Points are colored based on previously-determined C-terminal type from
610 Cross et al., or by the source of the sequence (genomic or expressed) for *T. b. gambiense*
611 VSGs. B) Network plot showing peptide sequence relatedness between C-terminal domains in
612 *T. b. gambiense* expressed VSGs. Each point represents a VSG C-terminus; a link was drawn
613 between points if BLASTp e-value was less than 1×10^{-3} . Points are colored by cluster
614 determined by the clustering algorithm. Clusters are also indicated by shaded circles. C) Same
615 network plot as in B, but colored by previously-determined C-terminal type from Cross et al., or
616 by source for unclassified genomic or expressed VSGs. D) VSG C-terminal types, based on
617 cluster assignment visualized in panel B, in genomic and expressed VSG sets. E) Pairing of C-
618 and N-termini in *T. b. gambiense* patients. F) C-termini detected in each patient village.

619 Discussion

620
621 African trypanosomes evade the host adaptive immune response through a process of
622 antigenic variation, where parasites switch their expressed VSG [60]. The genome of *T.*
623 *brucei* encodes a large repertoire of VSG genes, pseudogenes, and gene fragments,
624 and can be extended continuously through recombination to form entirely novel
625 “mosaic” VSGs [17]. While antigenic variation has been studied extensively in culture
626 and in animal models of infection, our understanding of the process in natural infections,
627 particularly human infection, is limited. Most experimental mouse infections are
628 sustained for weeks to months, while humans and large mammals may be infected for
629 several months or even years. Additionally, laboratory studies of antigenic variation
630 almost exclusively use *T. b. brucei*, a subspecies of *T. brucei* that, by definition, does
631 not infect humans.

632
633 The primary hurdle to exploring antigenic variation in nature has been technical: it is
634 difficult to obtain sufficient parasite material for analysis. This is especially true for
635 infection with *T. b. gambiense*, which often exhibits extremely low parasitemia. VSG-
636 seq, which relies on PCR and requires very small amounts of material for analysis,
637 provides a new tool for exploring VSG expression in natural human infections. Here we
638 have demonstrated the feasibility of VSG-seq to analyze VSG expression in RNA
639 samples isolated directly from HAT patients. Our analyses show that the diversity seen
640 in mouse models of infection is mostly recapitulated in natural infection, but that there
641 may be unique aspects of antigenic variation in *T. b. gambiense* that can only be
642 explored by studying natural infections.

643
644 In our previous analysis of mouse infections, the most notable result was the diversity of
645 VSGs expressed. Rather than a few VSGs expressed at a time, we saw many VSGs
646 expressed simultaneously in the populations, confirming previous estimates of antigenic
647 diversity in experimental mouse infection [17] and suggesting that the genomic VSG
648 repertoire might be exploited very rapidly. In the study presented here, we detected
649 several expressed VSGs in most *T. b. gambiense* samples. Although diversity in *T. b.*
650 *gambiense* infection appeared lower overall, the correlation we observed between
651 parasitemia and diversity in *T. b. gambiense* isolates specifically suggests that our
652 sampling was incomplete. Indeed, in our analysis of *T. b. rhodesiense* infection (a more
653 reasonable comparison to mouse infection given similar expression cutoffs and
654 parasitemia), we observed diversity similar to or higher than what we have detected in
655 *T. b. brucei* mouse infections. Moreover, *T. b. rhodesiense* patient CSF revealed
656 another layer of diversity in VSG expression, with 5 VSGs expressed exclusively in this
657 space. Overall, our analysis of VSG expression in *T. b. gambiense* and *T. b.*
658 *rhodesiense* patients confirmed the long-held assumption that VSG diversity is a feature
659 of natural infection.

660
661 While analyzing the sets of expressed VSGs in *T. b. gambiense* and *T. b. rhodesiense*
662 infections, we found evidence for another feature of experimental infection that holds
663 true in a natural host: hierarchical VSG expression. Both *in vitro* and *in vivo* studies
664 have shown that VSG switching is not entirely stochastic but rather hierarchical, with

665 certain variants dominating expression in the parasite population in a reproducible order
666 that appears to be independent of the starting VSG [17,31,32,61,62]. Switching
667 hierarchy is hypothesized to be determined by multiple factors including homology,
668 gene size, and genomic location. In the *T. b. gambiense* samples, we found two VSGs
669 that met our detection threshold in multiple patients, and in *T. b. rhodesiense* a large
670 proportion of expressed VSGs were shared among multiple patients. Given the large
671 size of the genomic VSG repertoire, any overlap in expressed VSG repertoire is likely
672 indicative of a semi-predictable hierarchy of switching and preference for the expression
673 of certain VSGs.

674
675 Of the two shared VSGs we identified in the *T. b. gambiense* patients, one was
676 identified in two patients from the same village, while the other was found in two
677 patients from villages 40km apart. At this short distance, it is possible that the infecting
678 parasites were genetically similar and thus this overlap simply reflects preference in
679 switching. It would be interesting to investigate, however, whether preference for the
680 expression of certain VSGs occurs even between parasites isolated at greater
681 distances. Indeed, it has been shown that the sensitivity of serological tests for gHAT,
682 which detect antibody against the LiTat 1.3 VSG, vary regionally, potentially due to
683 differences in the underlying genomic or expressed VSG repertoire in circulating strains
684 [63,64]. Along these same lines, none of our assembled *T. b. gambiense* VSGs from
685 patients in the DRC shared significant similarity with those in the genome of DAL972, a
686 parasite isolate from Côte d'Ivoire. This could suggest that there are geographic
687 variations in *T. brucei* VSG repertoires. Similar variation has been observed in *var* gene
688 repertoires of *Plasmodium falciparum* [65] and the VSG repertoire of *Trypanosoma*
689 *vivax*, another African trypanosome [35]. A better understanding of such differences in
690 *T. brucei*, if they exist, could lead to development of more sensitive HAT diagnostics.

691
692 To better understand the VSG proteins expressed in natural infections, we developed
693 an HMM VSG typing pipeline that revealed an intriguing bias in *T. b. gambiense*
694 infection towards type B VSGs that appears to be specific to *T. b. gambiense* patient
695 samples. While small sample sizes and important differences between each *T. brucei*
696 subspecies' dataset limit the conclusions that can be drawn, comparisons between
697 these sets do suggest that the genomic VSG repertoire determines the distribution of
698 VSG N-terminal types expressed during *T. brucei* infection and may account for the bias
699 we have observed in *T. b. gambiense* patients.

700
701 Our analysis of experimental mouse infections suggests that while the predominant
702 expressed N-terminal domain type fluctuates between type A and type B over time,
703 even into advanced stages of infection, the repertoire expressed over the course of an
704 infection generally reflects the composition of the genomic VSG repertoire of the
705 infecting parasite strain. A direct comparison between the genomic VSG repertoire and
706 the expressed VSG repertoire can be made for experimental *T. b. brucei* EATRO1125
707 infections, as the EATRO1125 VSGnome was generated from the same parasite strain
708 used to initiate these infections. Such a direct comparison is impossible for patient
709 samples. While the content of the 'core' *T. brucei* genome (containing the diploid,
710 housekeeping genes) is similar enough among subspecies for resequencing projects to

711 be scaffolded using the TREU927 or Lister 427 reference genomes [59,66,67], it is not
712 clear whether the VSG repertoires of subspecies (or even individual parasite strains
713 [36]) share this degree of similarity. Although a near-complete VSGnome for any *T. b.*
714 *rhodesiense* strain was not available, we chose to compare the makeup of *T. b.*
715 *rhodesiense* expressed VSGs with the well-characterized genome of *T. b. brucei* Lister
716 427 [16], given the extreme similarity between *T. b. brucei* and *T. b. rhodesiense* [59].
717 Similarly, we compared expressed VSGs in *T. b. gambiense* patients to the limited set
718 of VSGs in the *T. b. gambiense* DAL972 genome. In both cases, the distribution of N-
719 terminal types expressed in infection was not significantly different from that of the
720 genomic VSG repertoire to which the expressed VSGs were being compared. Taken
721 together, these data support a model in which VSG types are drawn from the repertoire
722 at roughly equal frequency to their representation in the genome, and that that the *T. b.*
723 *gambiense* VSG repertoire may contain a larger proportion of type B VSG than its more
724 virulent counterparts.

725
726 Another possibility we cannot rule out is that the gHAT samples are biased due to
727 selection by the serological test used for diagnosis. Patients were screened for *T. b.*
728 *gambiense* infection using the CATT, a serological test that uses parasites expressing
729 VSG LiTat 1.3 as an antigen. LiTat 1.3 contains a type B2 N-terminal domain [63,64]. It
730 is possible that patients infected with parasites predominantly expressing type B VSGs
731 are more likely to generate antibodies that cross-react with LiTat1.3, resulting in
732 preferential detection of these cases. In contrast, *T.b. rhodesiense* can only be
733 diagnosed microscopically, removing the potential to introduce bias through screening.
734 It remains to be investigated whether samples from patients diagnosed using newer
735 screening tests, which include the invariant surface glycoprotein ISG65 and the type A
736 VSG LiTat 1.5 [29], would show similar bias towards expression of type B VSGs.

737
738 Analysis of expressed VSG C-terminal domains in *T. b. gambiense* patients showed a
739 bias towards C-terminal types 1 and 2. The diagnostic VSG LiTat1.3 contains a type 3
740 C-terminus, a C-terminal type which was underrepresented in the patient set. Therefore,
741 it is unlikely that a bias in expressed C-terminal types is related to the screening
742 method. Notably, the bias towards C-terminal types 1 and 2 was not reflected in the
743 limited VSG repertoire of the DAL972 reference genome or the repertoire of the Lister
744 427 *T. b. brucei* reference genome. This could be related to the limited set of VSGs
745 present in the DAL972 reference genome, or it could suggest a true bias in expression.

746
747 Could a bias towards certain VSG types, whether due to a difference in repertoire
748 composition or expression preference, account for the chronic nature of gHAT? While
749 the genomic VSG repertoire has been analyzed extensively in laboratory strains, little is
750 known about how differences in VSG proteins relate to parasite biology or whether there
751 could be biological consequences to the expression of specific VSG N- or C-terminal
752 types. Type A *var* genes in *Plasmodium falciparum* infection have been shown to be
753 associated with severe malaria [68–72], and similar mechanisms have been
754 hypothesized to exist in *T. vivax* and *T. congolense* infections [33,35,73,74]. In *T.*
755 *brucei*, several VSGs have evolved specific functions besides antigenic variation [74].
756 Recently, the first type B VSG structure was solved [75], revealing a unique O-linked

757 carbohydrate in the VSG's N-terminal domain. This modification was found to interfere
758 with the generation of protective immunity in a mouse model of infection; perhaps
759 structural differences between each VSG type, including patterns of glycosylation, could
760 influence infection outcomes. Further research will be needed to determine whether the
761 observed predominance of type B VSGs could influence the clinical presentation of *T. b.*
762 *gambiense* infection.

763
764 Currently, it is unclear why this collection of gHAT patient isolates demonstrates a bias
765 towards expression of certain VSG types. More research will be needed to determine
766 whether the *T. b. gambiense* VSG repertoire contains a unique distribution of VSG
767 types, whether these parasites preferentially express certain VSG types, and whether
768 this bias could have functional consequences. What this study has shown, however, is
769 that it is feasible to explore antigenic variation in natural infection and that, although
770 mouse models do reflect the general dynamics of antigenic variation in natural *T. brucei*
771 infection, unique biology remains to be uncovered by studying antigenic variation in its
772 natural context.

773
774
775
776

777 **Acknowledgments**

778

779 We are very grateful to the patients without whom this work would not have been
780 possible. We thank George Cross and Danae Schulz for comments on the manuscript.
781 We would also like to thank Mary Gebhardt for help with GIS. The atlas of HAT is an
782 initiative of the World Health Organization (WHO), jointly implemented with the Food
783 and Agriculture Organization of the United Nations (FAO) in the framework of the
784 Programme Against African Trypanosomosis (PAAT).

785

786 **Supplement**

787

788 **Supplemental Table 1. Primer sequences.**

789

790 **Supplemental Table 2. gHAT patient distance matrix.**

791

792 **Supplemental Table 3. gHAT VSG expression data.**

793


794 **Supplemental Table 4. Tables comparing BLAST-tree, HMMscan, and network plot typing**
795 **methods.**

796

797 **Supplemental Table 5. rHAT VSG expression data.**


798

799



800
801
802


Supplemental Figure 1. Heatmap of all assembled *T. b. gambiense* patient VSGs



803
804
805
806
807
808
809
810

Supplemental Figure 2. Correlation between parasitemia and diversity and N-terminal type distribution. (A) Correlation plots for VSG diversity and percent of N-terminal domain type B for *T.b. brucei* infected mice from Mugnier et.al 2015. (B) Correlation plots for *T.b. rhodesiense* infected patients from Mulindwa et. al. 2018. (C) Correlation plots for *T.b. gambiense* infected patients.

811
812




813
814 **Supplemental Figure 3.** (A) Network plot showing peptide sequence relatedness between N-
815 terminal domains. Each point represents a VSG N-terminus. A link was drawn between points if
816 BLASTp e-value was less than 10^{-2} . Colors and shaded circles represent community
817 assignment determined by the clustering algorithm. (B) Same graph as in (A), but points are
818 manually colored by known N-terminal subtype from Cross et al., or by subspecies for VSGs
819 identified in patients.
820

821

822 **Supplemental Fig 4. BLASTp-tree of all *T. b. gambiense* VSGs.** File attached.

823

824



825

826 Supplemental Figure 5. Heatmap of all assembled *T.b. rhodesiense* patient VSGs

827

828

829

830

831 **References**

- 832 1. Romero-Meza G, Mugnier MR. *Trypanosoma brucei*. Trends in Parasitology.
833 2019. doi:10.1016/j.pt.2019.10.007
- 834 2. Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis.
835 www.thelancet.com. 2017;390. doi:10.1016/S0140-6736(17)31510-6
- 836 3. Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the
837 elimination of human African trypanosomiasis at continental and country level:
838 Update to 2018. PLoS Negl Trop Dis. 2020;14: e0008261.
839 doi:10.1371/JOURNAL.PNTD.0008261
- 840 4. Kennedy PGE, Rodgers J. Clinical and neuropathogenetic aspects of human
841 African trypanosomiasis. Frontiers in Immunology. Frontiers Media S.A.; 2019.
842 doi:10.3389/fimmu.2019.00039
- 843 5. Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, et al. Monitoring the
844 elimination of human African trypanosomiasis at continental and country level:
845 Update to 2018. PLoS Negl Trop Dis. 2020;14: e0008261.
846 doi:10.1371/JOURNAL.PNTD.0008261
- 847 6. WHO. The Global Health Observatory. In: WHO [Internet]. World Health
848 Organization; [cited 17 Aug 2021]. Available:
849 [https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/human-african-trypanosomiasis)
850 [details/GHO/human-african-trypanosomiasis](https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/human-african-trypanosomiasis)
- 851 7. WHO. Ending the neglect to attain the sustainable development goals: a road
852 map for neglected tropical diseases 2021–2030. Geneva; 2020.
- 853 8. Magez S, Caljon G, Tran T, Stijlemans B, Radwanska M. Current status of
854 vaccination against African trypanosomiasis. Parasitology. 2010;137: 2017–2027.
- 855 9. Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco
856 F, et al. *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the
857 Adipose Tissue in Mice. Cell Host Microbe. 2016;19: 837–848.
858 doi:10.1016/j.chom.2016.05.002
- 859 10. Pereira SS, Trindade S, De Niz M, Figueiredo LM. Tissue tropism in parasitic
860 diseases. Open Biology. Royal Society Publishing; 2019.
861 doi:10.1098/rsob.190036
- 862 11. Camara M, Soumah AM, Ilboudo H, Travaillé C, Clucas C, Cooper A, et al.
863 Extravascular Dermal Trypanosomes in Suspected and Confirmed Cases of
864 gambiense Human African Trypanosomiasis. Clin Infect Dis. 2021;73: 12–20.
865 doi:10.1093/cid/ciaa897
- 866 12. Alfituri OA, Bradford BM, Paxton E, Morrison LJ, Mabbott NA. Influence of the
867 Draining Lymph Nodes and Organized Lymphoid Tissue Microarchitecture on
868 Susceptibility to Intradermal *Trypanosoma brucei* Infection. Front Immunol.
869 2020;11. doi:10.3389/fimmu.2020.01118
- 870 13. Marcello L, Barry JD. Analysis of the VSG gene silent archive in *Trypanosoma*
871 *brucei* reveals that mosaic gene expression is prominent in antigenic variation and
872 is favored by archive substructure. Genome Res. 2007;17: 1344–1352.
- 873 14. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC,
874 et al. The genome of the African trypanosome *Trypanosoma brucei*. Sci (New
875 York, NY). 2005;309: 416–422.
- 876 15. Cross GAM, Kim H-S, Wickstead B. Capturing the variant surface glycoprotein

- 877 repertoire (the VSGnome) of *Trypanosoma brucei* Lister 427. *Mol Biochem*
878 *Parasitol.* 2014;195: 59–73. doi:10.1016/j.molbiopara.2014.06.004
- 879 16. Müller LSM, Cosentino RO, Förstner KU, Guizetti J, Wedel C, Kaplan N, et al.
880 Genome organization and DNA accessibility control antigenic variation in
881 trypanosomes. *Nature.* 2018;563: 121–125.
- 882 17. Hall JPJ, Wang H, Barry JD. Mosaic VSGs and the scale of *Trypanosoma brucei*
883 antigenic variation. Horn D, editor. *PLoS Pathog.* 2013;9: e1003502.
- 884 18. Jayaraman S, Harris C, Paxton E, Donachie A-M, Vaikkinen H, McCulloch R, et
885 al. Application of long read sequencing to determine expressed antigen diversity
886 in *Trypanosoma brucei* infections. Acosta-Serrano A, editor. *PLoS Negl Trop Dis.*
887 2019;13: e0007262. doi:10.1371/journal.pntd.0007262
- 888 19. Carrington M, Miller N, Blum M, Roditi I, Wiley D, Turner M. Variant specific
889 glycoprotein of *Trypanosoma brucei* consists of two domains each having an
890 independently conserved pattern of cysteine residues. *J Mol Biol.* 1991;221: 823–
891 835.
- 892 20. Hutchinson OC, Smith W, Jones NG, Chattopadhyay A, Welburn SC, Carrington
893 M. VSG structure: similar N-terminal domains can form functional VSGs with
894 different types of C-terminal domain. *Mol Biochem Parasitol.* 2003;130: 127–131.
- 895 21. Jones NG, Nietlispach D, Sharma R, Burke DF, Eyres I, Mues M, et al. Structure
896 of a glycosylphosphatidylinositol-anchored domain from a trypanosome variant
897 surface glycoprotein. *J Biol Chem.* 2008;283: 3584–3593.
- 898 22. Schwede A, Jones N, Engstler M, Carrington M. The VSG C-terminal domain is
899 inaccessible to antibodies on live trypanosomes. *Mol Biochem Parasitol.*
900 2011;175: 201–204.
- 901 23. Van Meirvenne N, Magnus E, Büscher P. Evaluation of variant specific
902 trypanolysis tests for serodiagnosis of human infections with *Trypanosoma brucei*
903 *gambiense*. *Acta Trop.* 1995;60: 189–199. doi:10.1016/0001-706X(95)00127-Z
- 904 24. A card-agglutination test with stained trypanosomes (C. A. T.T.) for the serological
905 diagnosis of *T. b. gambiense* tripanosomiasis. [cited 8 Sep 2021]. Available:
906 <https://www.cabdirect.org/cabdirect/abstract/19792901755>
- 907 25. Dukes P, Gibson WC, Gashumba JK, Hudson KM, Bromidge TJ, Kaukus A, et al.
908 Absence of the LiTat 1.3 (CATT antigen) gene in *Trypanosoma brucei gambiense*
909 stocks from Cameroon. *Acta Trop.* 1992.
- 910 26. Enyaru JCK, Allingham R, Bromidge T, Kanmogne GD, Carasco JF. The isolation
911 and genetic heterogeneity of *Trypanosoma brucei gambiense* from north-west
912 Uganda. *Acta Trop.* 1993.
- 913 27. Bisser S, Lumbala C, Nguertoum E, Kande V, Flevaud L, Vatunga G, et al.
914 Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection
915 of *Trypanosoma brucei gambiense* Infection: A Multi-centric Prospective Study.
916 Acosta-Serrano A, editor. *PLoS Negl Trop Dis.* 2016;10: e0004608.
917 doi:10.1371/journal.pntd.0004608
- 918 28. Büscher P, Mertens P, Leclipteux T, Gillemann Q, Jacquet D, Mumba-Ngoyi D, et
919 al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for
920 serodiagnosis of sleeping sickness caused by *Trypanosoma brucei gambiense*: A
921 case-control study. *Lancet Glob Heal.* 2014;2: e359–e363. doi:10.1016/S2214-
922 109X(14)70203-7

- 923 29. Lumbala C, Biéler S, Kayembe S, Makabuza J, Ongarello S, Ndung'u JM.
924 Prospective evaluation of a rapid diagnostic test for *Trypanosoma brucei*
925 gambiense infection developed using recombinant antigens. *PLoS Negl Trop Dis*.
926 2018;12: e0006386. doi:10.1371/JOURNAL.PNTD.0006386
- 927 30. Mugnier MR, Cross GAM, Papavasiliou FN. The in vivo dynamics of antigenic
928 variation in *Trypanosoma brucei*. *Science* (80-). 2015;347: 1470–1473.
929 doi:10.1126/science.aaa4502
- 930 31. Morrison LJ, Majiwa P, Read AF, Barry JD. Probabilistic order in antigenic
931 variation of *Trypanosoma brucei*. *Int J Parasitol*. 2005;35: 961–972.
- 932 32. Lythgoe KA, Morrison LJ, Read AF, Barry JD. Parasite-intrinsic factors can
933 explain ordered progression of trypanosome antigenic variation. *Proc Natl Acad*
934 *Sci U S A*. 2007;104: 8095–8100.
- 935 33. Silva Pereira S, Heap J, Jones AR, Jackson AP. VAPPER: High-throughput
936 variant antigen profiling in African trypanosomes of livestock. *Gigascience*.
937 2019;8. doi:10.1093/gigascience/giz091
- 938 34. Pereira SS, Casas-Sánchez A, Haines LR, Ogugo M, Absolomon K, Sanders M,
939 et al. Variant antigen repertoires in *Trypanosoma congolense* populations and
940 experimental infections can be profiled from deep sequence data using universal
941 protein motifs. *Genome Res*. 2018;28: 1383–1394. doi:10.1101/gr.234146.118
- 942 35. Silva Pereira S, de Almeida Castilho Neto KJG, Duffy CW, Richards P, Noyes H,
943 Ogugo M, et al. Variant antigen diversity in *Trypanosoma vivax* is not driven by
944 recombination. *Nat Commun*. 2020;11: 844. doi:10.1038/s41467-020-14575-8
- 945 36. Hutchinson OC, Picozzi K, Jones NG, Mott H, Sharma R, Welburn SC, et al.
946 Variant Surface Glycoprotein gene repertoires in *Trypanosoma brucei* have
947 diverged to become strain-specific. *BMC Genomics*. 2007;8: 234.
948 doi:10.1186/1471-2164-8-234
- 949 37. Ilboudo H, Noyes H, Mulindwa J, Kimuda MP, Koffi M, Kaboré JW, et al.
950 Introducing the TrypanoGEN biobank: A valuable resource for the elimination of
951 human African trypanosomiasis. *PLoS Negl Trop Dis*. 2017;11: e0005438.
952 doi:10.1371/JOURNAL.PNTD.0005438
- 953 38. Camara M, Camara O, Ilboudo H, Sakande H, Kaboré J, N'Dri L, et al. Sleeping
954 sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion
955 exchange centrifugation test. *Trop Med Int Heal*. 2010;15: 796–799.
956 doi:10.1111/J.1365-3156.2010.02546.X
- 957 39. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, et al. The Atlas of
958 human African trypanosomiasis: A contribution to global mapping of neglected
959 tropical diseases. *Int J Health Geogr*. 2010;9: 57. doi:10.1186/1476-072X-9-57
- 960 40. González-Andrade P, Camara M, Ilboudo H, Bucheton B, Jamonneau V,
961 Deborggraeve S. Diagnosis of trypanosomatid infections: Targeting the spliced
962 leader RNA. *J Mol Diagnostics*. 2014. doi:10.1016/j.jmoldx.2014.02.006
- 963 41. Brakenhoff RH, Schoenmakers JG, Lubsen NH. Chimeric cDNA clones: a novel
964 PCR artifact. *Nucleic Acids Res*. 1991;19: 1949. doi:10.1093/NAR/19.8.1949
- 965 42. Meyerhans A, Vartanian J-P, Wain-Hobson S. DNA recombination during PCR.
966 *Nucleic Acids Res*. 1990;18: 1687–1691. doi:10.1093/NAR/18.7.1687
- 967 43. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, et al. Full-
968 length transcriptome assembly from RNA-Seq data without a reference genome.

- 969 Nat Biotechnol. 2011;29: 644–652.
- 970 44. Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of
971 protein or nucleotide sequences. *Bioinformatics*. 2006;22: 1658–1659.
- 972 45. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
973 alignment of short DNA sequences to the human genome. *Genome Biol*. 2009;10:
974 R25.
- 975 46. Storvall H, Ramsköld D, Sandberg R. Efficient and comprehensive representation
976 of uniqueness for next-generation sequencing by minimum unique length
977 analyses. *PLoS One*. 2013;8: e53822.
- 978 47. Wickstead B, Gull K. Dyneins across eukaryotes: a comparative genomic
979 analysis. *Traffic*. 2007;8: 1708–1721.
- 980 48. Howe K, Bateman A, Durbin R. QuickTree: Building huge neighbour-joining trees
981 of protein sequences. *Bioinformatics*. 2002;18: 1546–1547.
982 doi:10.1093/bioinformatics/18.11.1546
- 983 49. Paradis E, Schliep K. Ape 5.0: An environment for modern phylogenetics and
984 evolutionary analyses in R. *Bioinformatics*. 2019;35: 526–528.
985 doi:10.1093/bioinformatics/bty633
- 986 50. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable
987 generation of high-quality protein multiple sequence alignments using Clustal
988 Omega. *Mol Syst Biol*. 2011;7: 539–539. doi:10.1038/msb.2011.75
- 989 51. Eddy SR. Accelerated Profile HMM Searches. *PLOS Comput Biol*. 2011;7:
990 e1002195. doi:10.1371/JOURNAL.PCBI.1002195
- 991 52. Csárdi G, Nepusz T. The igraph software package for complex network research.
- 992 53. Newman MEJ. Finding community structure in networks using the eigenvectors of
993 matrices. *Phys Rev E*. 2006;74: 036104. doi:10.1103/PhysRevE.74.036104
- 994 54. González-Andrade P, Camara M, Ilboudo H, Bucheton B, Jamonneau V,
995 Deborggraeve S. Diagnosis of trypanosomatid infections: targeting the spliced
996 leader RNA. *J Mol Diagn*. 2014;16: 400–404.
- 997 55. Berberof M, Pérez-Morga D, Pays E. A receptor-like flagellar pocket glycoprotein
998 specific to *Trypanosoma brucei gambiense*. *Mol Biochem Parasitol*. 2001;113:
999 127–138.
- 1000 56. Weirather JL, Wilson ME, Donelson JE. Mapping of VSG similarities in
1001 *Trypanosoma brucei*. *Mol Biochem Parasitol*. 2012;181: 141–152.
- 1002 57. Mulindwa J, Leiss K, Ibberson D, Kamanyi Marucha K, Helbig C, Melo do
1003 Nascimento L, et al. Transcriptomes of *Trypanosoma brucei rhodesiense* from
1004 sleeping sickness patients, rodents and culture: Effects of strain, growth
1005 conditions and RNA preparation methods. Salavati R, editor. *PLoS Negl Trop Dis*.
1006 2018;12: e0006280.
- 1007 58. De Greef C, Hamers R. The serum resistance-associated (SRA) gene of
1008 *Trypanosoma brucei rhodesiense* encodes a variant surface glycoprotein-like
1009 protein. *Mol Biochem Parasitol*. 1994;68: 277–284.
- 1010 59. Siström M, Evans B, Benoit J, Balmer O, Aksoy S, Caccone A. De Novo Genome
1011 Assembly Shows Genome Wide Similarity between *Trypanosoma brucei brucei*
1012 and *Trypanosoma brucei rhodesiense*. Louis EJ, editor. *PLoS One*. 2016;11:
1013 e0147660. doi:10.1371/journal.pone.0147660
- 1014 60. Mugnier MR, Stebbins CE, Papavasiliou FN. Masters of Disguise: Antigenic

- 1015 Variation and the VSG Coat in *Trypanosoma brucei*. Knoll LJ, editor. PLOS
1016 Pathog. 2016;12: e1005784. doi:10.1371/journal.ppat.1005784
- 1017 61. Aitcheson N, Talbot S, Shapiro J, Hughes K, Adkin C, Butt T, et al. VSG switching
1018 in *Trypanosoma brucei*: antigenic variation analysed using RNAi in the absence of
1019 immune selection. Mol Microbiol. 2006;57: 1608–1622. doi:10.1111/j.1365-
1020 2958.2005.04795.x.VSG
- 1021 62. Liu D, Albergante L, Newman TJ, Horn D. Faster growth with shorter antigens can
1022 explain a VSG hierarchy during African trypanosome infections: a feint attack by
1023 parasites. Sci Rep. 2018;8: 10922. doi:10.1038/s41598-018-29296-8
- 1024 63. Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P. Options for field diagnosis
1025 of human african trypanosomiasis. Clin Microbiol Rev. 2005;18: 133–146.
- 1026 64. Truc P, Lejon V, Magnus E, Jamonneau V, Nangouma A, Verloo D, et al.
1027 Evaluation of the micro-CATT, CATT/*Trypanosoma brucei gambiense*, and
1028 LATEX/T b gambiense methods for serodiagnosis and surveillance of human
1029 African trypanosomiasis in West and Central Africa. Bull World Health Organ.
1030 2002;80: 882–886.
- 1031 65. Tonkin-Hill G, Ruybal-Pesántez S, Tiedje KE, Rougeron V, Duffy MF, Zakeri S, et
1032 al. Evolutionary analyses of the major variant surface antigen-encoding genes
1033 reveal population structure of *Plasmodium falciparum* within and between
1034 continents. PLOS Genet. 2021;17: e1009269.
1035 doi:10.1371/JOURNAL.PGEN.1009269
- 1036 66. Jackson AP, Sanders M, Berry A, McQuillan J, Aslett MA, Quail MA, et al. The
1037 genome sequence of *Trypanosoma brucei gambiense*, causative agent of chronic
1038 human African Trypanosomiasis. PLoS Negl Trop Dis. 2010;4.
1039 doi:10.1371/journal.pntd.0000658
- 1040 67. Siström M, Evans B, Björnson R, Gibson W, Balmer O, Maser P, et al.
1041 Comparative genomics reveals multiple genetic backgrounds of human
1042 pathogenicity in the *trypanosoma brucei* complex. Genome Biol Evol. 2014;6:
1043 2811–2819. doi:10.1093/gbe/evu222
- 1044 68. Kirchgatter K, del Portillo HA. Association of Severe Noncerebral *Plasmodium*
1045 *falciparum* Malaria in Brazil With Expressed PfEMP1 DBL1 α Sequences Lacking
1046 Cysteine Residues. Mol Med 2002 81. 2002;8: 16–23. doi:10.1007/BF03401999
- 1047 69. Bull PC, Berriman M, Kyes S, Quail MA, Hall N, Kortok MM, et al. *Plasmodium*
1048 *falciparum* Variant Surface Antigen Expression Patterns during Malaria. PLOS
1049 Pathog. 2005;1: e26. doi:10.1371/JOURNAL.PPAT.0010026
- 1050 70. Abdi AI, Hodgson SH, Muthui MK, Kivisi CA, Kamuyu G, Kimani D, et al.
1051 *Plasmodium falciparum* malaria parasite var gene expression is modified by host
1052 antibodies: longitudinal evidence from controlled infections of Kenyan adults with
1053 varying natural exposure. BMC Infect Dis 2017 171. 2017;17: 1–11.
1054 doi:10.1186/S12879-017-2686-0
- 1055 71. Kyriacou HM, Stone GN, Challis RJ, Raza A, Lyke KE, Thera MA, et al.
1056 Differential var gene transcription in *Plasmodium falciparum* isolates from patients
1057 with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol.
1058 2006;150: 211–218. doi:10.1016/J.MOLBIOPARA.2006.08.005
- 1059 72. Duffy F, Bernabeu M, Babar PH, Kessler A, Wang CW, Vaz M, et al. Meta-
1060 analysis of *plasmodium falciparum* var signatures contributing to severe Malaria in

- 1061 African children and Indian adults. *MBio*. 2019;10. doi:10.1128/MBIO.00217-19
1062 73. Pereira SS, Casas-Sánchez A, Haines LR, Ogugo M, Absolomon K, Sanders M,
1063 et al. Variant antigen repertoires in *Trypanosoma congolense* populations and
1064 experimental infections can be profiled from deep sequence data using universal
1065 protein motifs. *Genome Res*. 2018;28: 1383. doi:10.1101/GR.234146.118
1066 74. Silva Pereira S, Jackson AP, Figueiredo LM. Evolution of the variant surface
1067 glycoprotein family in African trypanosomes. *Trends Parasitol*. 2021.
1068 doi:10.1016/J.PT.2021.07.012
1069 75. Pinger J, Nešić D, Ali L, Aresta-Branco F, Lilic M, Chowdhury S, et al. African
1070 trypanosomes evade immune clearance by O-glycosylation of the VSG surface
1071 coat. *Nat Microbiol*. 2018;19: 53.
1072